NewAmsterdam Pharma (NAMS) Competitors $23.55 +0.13 (+0.56%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NAMS vs. ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, and NUVLShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Ascendis Pharma A/S Roivant Sciences Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Cytokinetics Nuvalent NewAmsterdam Pharma (NASDAQ:NAMS) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Does the media favor NAMS or ASND? In the previous week, Ascendis Pharma A/S had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.65 beat Ascendis Pharma A/S's score of 0.64 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NAMS or ASND? NewAmsterdam Pharma currently has a consensus target price of $38.17, suggesting a potential upside of 62.07%. Ascendis Pharma A/S has a consensus target price of $192.07, suggesting a potential upside of 49.90%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Is NAMS or ASND more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -130.33%. Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Ascendis Pharma A/S -130.33%N/A -48.77% Which has more risk and volatility, NAMS or ASND? NewAmsterdam Pharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Which has preferable earnings & valuation, NAMS or ASND? NewAmsterdam Pharma has higher earnings, but lower revenue than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$14.09M154.42-$176.94MN/AN/AAscendis Pharma A/S$288.08M26.99-$521.07M-$8.08-15.86 Does the MarketBeat Community prefer NAMS or ASND? Ascendis Pharma A/S received 417 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 66.57% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes23100.00% Underperform VotesNo VotesAscendis Pharma A/SOutperform Votes44066.57% Underperform Votes22133.43% Do institutionals & insiders hold more shares of NAMS or ASND? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryNewAmsterdam Pharma beats Ascendis Pharma A/S on 9 of the 15 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$6.58B$5.36B$9.13BDividend YieldN/A2.94%5.13%4.03%P/E RatioN/A9.8389.4717.33Price / Sales154.42305.141,261.53136.12Price / CashN/A61.4443.7535.97Price / Book6.736.055.324.80Net Income-$176.94M$154.62M$122.60M$224.91M7 Day Performance-5.61%-1.68%0.69%1.77%1 Month Performance-11.50%-2.35%1.55%2.22%1 Year Performance40.60%1.02%27.25%20.67% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma2.6616 of 5 stars$23.55+0.6%$39.80+69.0%+40.6%$2.18B$14.09M0.004Analyst ForecastASNDAscendis Pharma A/S3.6193 of 5 stars$134.04+3.8%$192.07+43.3%-3.2%$8.13B$327.43M-16.59640Short Interest ↓ROIVRoivant Sciences3.689 of 5 stars$10.74+1.0%$17.93+66.9%+3.6%$7.82B$129.13M1.90860Insider TradeOptions VolumePositive NewsRVMDRevolution Medicines4.4701 of 5 stars$42.57+1.9%$66.25+55.6%+50.2%$7.16B$742,000.00-11.86250News CoverageLNTHLantheus4.5448 of 5 stars$94.65-1.3%$131.86+39.3%+65.5%$6.58B$1.50B15.75700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6713 of 5 stars$103.36+18.2%$122.72+18.7%+38.6%$6.57B$434.42M-48.99640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionGap UpHigh Trading VolumeBBIOBridgeBio Pharma4.0863 of 5 stars$33.73+16.0%$48.08+42.5%-8.5%$6.37B$217.77M-14.00400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.5041 of 5 stars$32.50-3.3%$80.62+148.0%-45.5%$5.94B$520.18M-34.211,800Short Interest ↓News CoverageELANElanco Animal Health4.415 of 5 stars$11.72+2.5%$16.43+40.2%-18.8%$5.79B$4.45B29.309,800CYTKCytokinetics4.313 of 5 stars$46.71+0.2%$83.64+79.1%-46.6%$5.51B$7.53M-8.68250Analyst ForecastNUVLNuvalent1.797 of 5 stars$72.09-5.9%$112.36+55.9%+2.7%$5.12BN/A-20.7840Analyst ForecastInsider TradeNews Coverage Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Lantheus Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NAMS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts